Table 1

Characteristics of studies included in the meta-analysis

First author, YearStudy designCountry enrolmentSample sizeAge in years, Mean (SD)Female, No (%)Race; White/Caucasian, No (%)Dialysis modalityData collectionFollow-up time
Abbott,23 2003RetrospectiveUSA123NRNRNRHD, PD1996–2000Mean 2.92±1.1 years
Chan,24 2009*RetrospectiveUSA1671 (1492 for PS-matched 1:1)72.4 (10.3)890 (59.7)1206 (80.8)HD2003–2007Mean 1.6 years, 2740 patient-years
Wizemann,9 2010ProspectiveInternational Collaboration3245≤65 (30.9%)
66–75 (35.0%)
>75 (34.1%)
NRNRHDDOPPS I; 1996–2001, DOPPS II; 2002–20044348 patient-years
Winkelmayer,25 2011*RetrospectiveUSA1185 for PS matched 1:469.4 (11.9)1329 (57.5)1498 (64.8)HD, PD1994–20062287patient-years
Bonde,26 2014RetrospectiveDenmark1680NRNRNRHD, PD1997–2010NR
Shah,27 2014RetrospectiveCanada162675.2 (8.3)634 (39.0)NRHD, PD1998–2007NR
Wakasugi,28 2014ProspectiveJapan6068.1 (8.9)21 (35.0)0HD2008–2011110 patient-years
Chan,29 2015ProspectiveUSA. Columbia, and the Territory of Puerto Rico14 60770.2 (10.8)5910 (40.5)10 902 (74.6)HD2010–20147260 patient-years
Chan,30 2015RetrospectiveHong Kong, China27170.4 (11.1)109 (40.2)0 (0.0)PD1997–20111.5 years
Genovesi,31 2015ProspectiveItaly290<65 (20.7%)
65–74 (25.9%)
≥75 (53.4%)
116 (40.0)NRHD2010–20122 years
Mitsuma,32 2015RetrospectiveJapan8270.7 (9.6)23 (28.0)0 (0.0)HD2011–2015Mean 3.0 years (423 patient; AF and non-AF)
Shen,33 2015RetrospectiveUSA12 284 (3658 for PS-matched 1:1)61.7 (13.4)6284 (51.2)6082 (49.5)HD2007–201116 617 patient-years
Wang,34 2015RetrospectiveNew Zealand14161.2 (11.3)54 (38.3)53 (37.6)HD, PD2000–2014Mean 3.4±2.5 years
Yodogawa,35 2015RetrospectiveJapan8470 (10.4)25 (29.8)0 (0.0)HD2003–2012Mean 3.9 years
First author, YearWarfarin use defined asWarfarin use, No. (%)Comparison groupStroke risk stratificationBleeding risk stratificationOutcomes reportedTotal NOS Score
Abbott,23 2003Baseline use; day 60 of dialysisNRNon-warfarin users (non-specify)NRNRAll-cause mortality7
Chan,24 2009*Baseline use; any use in the first 90 days746 (44.6)Non-warfarin users (placebo/clopidogrel/aspirin/clopidogrel+aspirin)CHADS2 scoreNRAll-cause mortality, cardiovascular death, stroke/TE, bleeding events8
Wizemann,9 2010NR509 (15.7)Non-warfarin users (non-specify)NRNRStroke/TE7
Winkelmayer,25 2011*Baseline use; prescription within 30 days from index date249 (10.8)Non-warfarin users (non-specify)NRNRAll-cause mortality, stroke/TE, bleeding events7
Bonde,26 2014Baseline useNRNon-warfarin users (no antithrombotic)CHA2DS2-VASc scoreModified HAS-BLED score†All-cause mortality, cardiovascular death8
Shah,27 2014Baseline use; prescription within 30 days from index date756 (46.5)Non-warfarin users (non-specify)CHADS2 scoreModified HAS-BLED score‡stroke/TE, bleeding events8
Wakasugi,28 2014Baseline use28 (46.7)Non-warfarin users (non-specify)CHADS2 scoreNRAll-cause mortality, stroke/TE, bleeding events7
Chan,29 2015Baseline use8064 (55.2)Non-warfarin users (aspirin/dabigatran/rivaroxaban)CHADS2 scoreOutpatient Bleeding Risk Indexstroke/TE, bleeding events9
Chan,30 2015Baseline use67 (24.7)Non-warfarin users (placebo/aspirin)CHA2DS2-VASc scoreHAS-BLED scoreStroke/thromboembolism7
Genovesi,31 2015Baseline use; prescription at recruitment or starting within 2 weeks following recruitment156 (53.8)Non-warfarin users (non-specify)CHA2DS2-VASc scoreModified HAS-BLED score†All-cause mortality, cardiovascular death, stroke/TE, bleeding events8
Mitsuma,32 2015Baseline use27 (32.9)Non-warfarin users (non-specify)NRNRAll-cause mortality, cardiovascular death7
Shen,33 2015Baseline use; prescription within 30 days from index date1838 (15.0)Non-warfarin users (non-specify)CHADS2 scoreModified HAS-BLED score†All-cause mortality, cardiovascular death, stroke/TE, bleeding events9
Wang,34 2015Baseline use59 (41.8)Non-warfarin users (placebo/clopidogrel/aspirin)CHADS2/CHA2DS2-VASc scoreHAS-BLED scoreAll-cause mortality, stroke/TE, bleeding events7
Yodogawa,35 2015Baseline use30 (35.7)Non-warfarin users (non-specify)CHADS2 scoreNRAll-cause mortality, stroke/TE7
  • *Data based on propensity score-matched.

  • †Modified HAS-BLED score for estimating the risk for bleeding (not included the score related to labile INR).

  • ‡Modified HAS-BLED score for estimating the risk for bleeding (not included the score related to labile INR and alcohol intake). AF, atrial fibrillation; HD, haemodialysis; INR, international normalised ratio; NOS, the Newcastle-Ottawa Scale; NR; not reported; PD, peritoneal dialysis; PS, propensity score; TE, thromboembolism.